NovoCure Limited (NASDAQ:NVCR) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $19.85 to $22.65 in the past one-month time frame.
The move came after the company reported favorable top-line results from the STELLAR phase 2 pilot trial in mesothelioma.
The company has not seen any estimate revisions in the past month, while our Zacks Consensus Estimate has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
NovoCure currently has a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked stock in the Medical Services industry is HealthEquity, Inc. (NASDAQ:HQY) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is NVCR going up? Or down? Predict to see what others think: Up or Down
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax (NYSE:EFX) announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
HealthEquity, Inc. (HQY): Free Stock Analysis Report
NovoCure Limited (NVCR): Free Stock Analysis Report
Original post
Zacks Investment Research